Questions across 2 calls

Alankar Garude

Firm not listed in source transcripts

Mankind Pharma Limited

Mankind Pharma Limited CC-May26.pdf · 2026-05-20

Hi, thank you for the opportunity. This is Alankar Garude from Kotak Institutional Equities. Sir, firstly, while you explained the points on staff cost as well as SG&A, in general, can you take us through the cost optimization initiatives ta ken over the last few quarters a nd how will you ensure that these do not impact your growth prospects over the medium to long term?

Sir, even on SG&A, I mean, you spoke about the high base because of the launches in the previous quarter. But even then, I mean, there has been a pretty good we've seen that moderate quite a bit. So anything we have done on the SG&A front as well, which you would like to call out? And yes, I mean, if you can also help elaborate on the point on growth impact from a more medium to long-term standpoint. Any impact at all which could potentially happen because of some of these initiatives?

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited CC-May26.pdf ·

Hi, good morning everyone. Just one question. Dilip Bhai, over the years you would have evaluated several assets from an acquisition standpoint. Now while Organon offers scale as you and Kirti sir mentioned, you will have to work on growth. In that contex t, what was the single biggest reason that made you bid for Organon and can you elaborate on that reason?

Just one follow -up there. If I look at the growth profile and especially the pipeline of Organon seems to be a bit sparse. You mentioned about the licensing opportunities as well as the global commercial footprint. So when you say that the endeavour is to pick a lead, a higher growth in Organon, is it going to be more of a long-term effort or do you see growth picking up in Organon over the next few years? For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com,